Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
94 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2014', provides an overview of the Opioid-Induced Constipation (OIC)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Opioid-Induced Constipation (OIC) Overview 8 Therapeutics Development 9 Pipeline Products for Opioid-Induced Constipation (OIC) - Overview 9 Pipeline Products for Opioid-Induced Constipation (OIC) - Comparative Analysis 10 Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies 11 Opioid-Induced Constipation (OIC) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Opioid-Induced Constipation (OIC) - Products under Development by Companies 16 Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development 17 Shionogi & Co., Ltd. 17 AstraZeneca PLC 18 Cubist Pharmaceuticals, Inc. 19 Progenics Pharmaceuticals, Inc. 20 Cosmo Pharmaceuticals S.p.A 21 Sucampo Pharmaceuticals, Inc. 22 Ironwood Pharmaceuticals, Inc. 23 AIKO Biotechnology, Inc. 24 Synergy Pharmaceuticals, Inc. 25 S.L.A. Pharma AG 26 Develco Pharma Schweiz AG 27 Opioid-Induced Constipation (OIC) - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Combination Products 29 Assessment by Target 30 Assessment by Mechanism of Action 33 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 naloxegol - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 lubiprostone - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 methylnaltrexone bromide - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 naldemedine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 bevenopran - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 naloxone hydrochloride PR - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 methylnaltrexone bromide - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 axelopran - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 naloxone hydrochloride SR - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 SP-333 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 linaclotide - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 naloxone hydrochloride - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 (6-beta-naltrexol + oxycodone) - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Opioid-Induced Constipation (OIC) - Recent Pipeline Updates 63 Opioid-Induced Constipation (OIC) - Dormant Projects 82 Opioid-Induced Constipation (OIC) - Discontinued Products 83 Opioid-Induced Constipation (OIC) - Product Development Milestones 84 Featured News & Press Releases 84 Jul 23, 2014: Sucampo Announces Publication of NICE Recommendation for AMITIZA (Lubiprostone) 84 Jul 17, 2014: Synergy Pharmaceuticals Completes Patient Enrollment for its SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation 84 Jul 14, 2014: FDA Office of Drug Evaluation III Approves Salix's Request that the FDA Approve the RELISTOR Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain 85 Jul 07, 2014: Swissmedic Approves AMITIZA (Lubiprostone) for the Treatment of Opioid-Induced Constipation 86 Jun 19, 2014: Data Published In The New England Journal Of Medicine Demonstrate Naloxegol Improved Opioid-Induced Constipation In Chronic Pain Patients 86 Jun 17, 2014: AMITIZA (Lubiprostone) Receives NICE Recommendation 88 Jun 12, 2014: Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting's Vote 89 Jun 12, 2014: FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC 89 Jun 12, 2014: US FDA advisory committee recommends no cardiovascular outcomes trial for peripherally-Acting MU-Opioid Receptor Antagonist (Pamora) class including Movantik 90 Jun 04, 2014: Drug trial shows promise for treating constipation caused by pain medicines 91 Appendix 93 Methodology 93 Coverage 93 Secondary Research 93 Primary Research 93 Expert Panel Validation 93 Contact Us 94 Disclaimer 94
List of Tables Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2014 9 Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H2 2014 17 Opioid-Induced Constipation (OIC) - Pipeline by AstraZeneca PLC, H2 2014 18 Opioid-Induced Constipation (OIC) - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 19 Opioid-Induced Constipation (OIC) - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 20 Opioid-Induced Constipation (OIC) - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2014 21 Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2014 22 Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2014 23 Opioid-Induced Constipation (OIC) - Pipeline by AIKO Biotechnology, Inc., H2 2014 24 Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H2 2014 25 Opioid-Induced Constipation (OIC) - Pipeline by S.L.A. Pharma AG, H2 2014 26 Opioid-Induced Constipation (OIC) - Pipeline by Develco Pharma Schweiz AG, H2 2014 27 Assessment by Monotherapy Products, H2 2014 28 Assessment by Combination Products, H2 2014 29 Number of Products by Stage and Target, H2 2014 32 Number of Products by Stage and Mechanism of Action, H2 2014 35 Number of Products by Stage and Route of Administration, H2 2014 37 Number of Products by Stage and Molecule Type, H2 2014 39 Opioid-Induced Constipation (OIC) Therapeutics - Recent Pipeline Updates, H2 2014 63 Opioid-Induced Constipation (OIC) - Dormant Projects, H2 2014 82 Opioid-Induced Constipation (OIC) - Discontinued Products, H2 2014 83
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.